Health Journal Online

Category: Diseases & Conditions

  • Seniors Taking Antidepressants May Benefit from Adding a Daily Probiotic, New Clinical Trial Finds

    Seniors Taking Antidepressants May Benefit from Adding a Daily Probiotic, New Clinical Trial Finds

    A small but carefully designed clinical trial has added meaningful weight to the idea that gut health and mood are biologically connected — with practical implications for millions of older Americans living with depression.

    The trial, published June 17, 2026, in the Journal of the American Geriatrics Society (JAGS), enrolled 58 adults aged 60 and older with moderate depression. Participants were randomly assigned to receive either a daily probiotic supplement (containing Lactobacillus helveticus and Bifidobacterium longum) or a placebo for 12 weeks, while both groups continued their prescribed antidepressant treatment.

    The result: older adults who added the probiotic experienced meaningfully greater reductions in both depressive and anxiety symptoms than those who received the placebo.

    Why This Matters

    Depression is common in older adults and difficult to treat. Standard antidepressants are effective in roughly half of patients — a success rate that leaves millions without adequate relief. In older adults specifically, antidepressant response rates are lower still, side effects are more pronounced, and polypharmacy (taking many medications simultaneously) adds complexity to treatment decisions.

    A daily probiotic is inexpensive, widely available without a prescription, and has a well-established safety profile in healthy older adults. If it can augment the effect of antidepressants already being taken — with no significant drug interactions — that is a meaningful low-risk option worth discussing with a physician.

    The qualification is equally important: this was a pilot trial of 58 people. It is preliminary evidence, not a treatment recommendation.

    What We Know So Far

    The PRODG trial (Efficacy of Adjunct PRObiotics in Moderate Unipolar Depression in Geriatric Patients) is described by its authors as the first randomized, double-blind, placebo-controlled trial specifically designed to test probiotic adjunct therapy in a geriatric depression population.

    According to ScienceDaily and Nutrition Insight reporting on the study, participants received either Lactobacillus helveticus and Bifidobacterium longum (approximately 6 billion CFU daily) or a placebo. Both groups continued their standard antidepressant treatment throughout.

    Both groups showed substantial overall improvements over the 12-week period — a pattern typical of depression trials, where placebo response is often significant. The probiotic group showed meaningfully greater benefit. Researchers also found elevated serum levels of BDNF (brain-derived neurotrophic factor) — a protein that supports neuron survival and growth — in the probiotic group, and measurable shifts in gut bacteria composition consistent with enhanced gut-brain axis signaling.

    What the Evidence Shows — and What It Does Not

    MedicalDaily Evidence Check

    • Study type: Randomized, double-blind, placebo-controlled pilot clinical trial (PRODG)
    • Participants: 58 adults aged 60 and older with moderate depression
    • Treatment: Lactobacillus helveticus + Bifidobacterium longum (~6 billion CFU daily) vs. placebo for 12 weeks, alongside standard antidepressant treatment
    • Published in: Journal of the American Geriatrics Society, June 17, 2026
    • What it found: Meaningfully greater reduction in depression and anxiety symptoms in the probiotic group; elevated BDNF levels; measurable shifts in gut bacteria composition
    • What it did not find: Significant improvement in quality of life or cognitive performance (possibly due to small sample size)
    • Key limitation: 58 participants is small. The trial was conducted in India; how well findings translate to other populations requires further study. A larger confirmatory trial is planned but not yet conducted.
    • What readers should know: This is promising preliminary evidence for a low-risk, low-cost intervention. Discuss with a physician before adding any supplement to an existing treatment regimen.

    Co-corresponding author Saibal Das, MBBS, MD, DM, PhD of the Indian Council of Medical Research stated: “The results of our study are novel, and we are now planning a follow-up, larger-scale clinical trial due to the encouraging findings.”

    What Doctors and Experts Say

    The gut-brain axis — the bidirectional communication network between the gastrointestinal microbiome and the central nervous system — has gained substantial scientific credibility over the past decade. Microbial diversity decreases with age, and communities shift toward pro-inflammatory configurations that may parallel the neuroinflammatory processes observed in geriatric depression.

    Dr. Abhinaba Ghosh, physician and neuroscientist at Tata Medical Center, and lead author, said: “We found that adding specific strains of probiotics has the potential to enhance improvement in depression and anxiety. We did not see a change in the quality of life of the patients, probably because this is a pilot study and there weren’t enough patients. We plan to address this in a follow-up full-scale clinical trial.”

    Psychiatrists reviewing the data have noted that the biological plausibility is sound, the safety profile is established, and the low cost makes the risk-benefit ratio favorable enough to be a reasonable discussion item between patients and their physicians.

    Who Faces the Greatest Risk?

    Older adults with depression who have not achieved adequate symptom relief with their current antidepressant regimen are the primary population for whom this discussion is most relevant. People who are not responding well to treatment, who want low-risk supplementary options, and who are otherwise healthy without contraindications to probiotic use are the most appropriate candidates for this conversation.

    People who are immunocompromised — including those undergoing chemotherapy, taking immunosuppressants, or with HIV — should consult their physician before starting any probiotic, as probiotics carry a small risk of translocation (movement of bacteria into the bloodstream) in severely immunocompromised individuals.

    What You Can Do Now

    • If you are an older adult taking antidepressants and are not achieving adequate symptom relief, ask your physician whether adding a probiotic supplement is something worth trying as an adjunct to your current treatment.
    • The specific strains used in the trial were Lactobacillus helveticus and Bifidobacterium longum. Products containing these strains are widely available at pharmacies without a prescription.
    • Do not stop or change your antidepressant without discussing it with your physician first. The trial showed benefit from adding a probiotic alongside existing treatment — not from replacing it.
    • If you are immunocompromised or have serious gastrointestinal conditions, consult your physician before starting any probiotic supplement.
    • Monitor for the larger confirmatory trial, which the research team says is in planning.

    Cost and Access: What Patients Should Know

    Probiotic supplements are widely available at pharmacies and grocery stores without a prescription, typically costing $15 to $40 per month. They are not covered by most insurance plans but are accessible to most people without financial hardship. A physician’s recommendation is not required to purchase them, but discussing any supplement change with your prescribing physician is advisable to ensure there are no contraindications with existing medications.

    What Happens Next

    The research team has announced plans for a larger, full-scale confirmatory trial. No timeline has been publicly specified. Until that trial is completed, the PRODG results should be treated as promising preliminary evidence warranting further study — not as established treatment guidance. MedicalDaily will report on the confirmatory trial results when published.

    The Bottom Line

    A well-designed pilot trial has found that seniors with depression who added a daily probiotic to their antidepressant showed greater improvement than those on placebo, meaningfully, with biological markers to support the finding. The evidence is preliminary, the sample is small, and a larger trial is needed. But the safety profile is good, the cost is low, and the risk-benefit conversation with a physician is reasonable. If you are an older adult who is not getting adequate relief from antidepressants, this is worth asking your doctor about.

    References

    Source link

  • The Most Effective Community Mental Health Clinic Model Just Received More Than 3 Million in New Federal Funding

    The Most Effective Community Mental Health Clinic Model Just Received More Than $223 Million in New Federal Funding

    The most evidence-based community mental health delivery model in the United States just received its largest single infusion of federal funding in years. On June 17, 2026, HHS Secretary Robert F. Kennedy Jr. announced more than $700 million in new behavioral health investments — including $223.1 million specifically for Certified Community Behavioral Health Clinics (CCBHCs) — during a visit to an Easterseals MORC CCBHC clinic in Clinton Township, Michigan.

    The announcement also introduced the STREETS program ($96 million), designed to connect people experiencing homelessness to addiction and mental health treatment, and $211.1 million to improve local 988 crisis line capacity. The total package represents one of the most significant federal investments in community behavioral health since the Bipartisan Safer Communities Act of 2022.

    Why This Matters

    The United States faces a profound mental health and substance use disorder crisis that costs lives and strains emergency rooms, jails, hospitals, and families. More than 57 million adults in the U.S. experienced a mental illness in the past year, and more than 28 million had a substance use disorder. Fewer than half of those with mental illness received any treatment.

    The CCBHC model was specifically designed to close that gap. Unlike traditional outpatient mental health clinics that operate on business hours and serve only those who can afford to wait, CCBHCs must provide same-day care regardless of patients’ ability to pay, 24-hour mobile crisis response, integrated treatment for both mental illness and substance use disorders, peer support services, and primary care screening.

    And unlike many promising models in mental health, CCBHCs have been rigorously studied — and the evidence works.

    What We Know So Far

    According to SAMHSA’s grants dashboard, the $223.1 million for CCBHCs breaks down as $94 million for CCBHC Planning, Development, and Implementation grants and $117.1 million for CCBHC Improvement and Advancement grants, plus $12 million for state planning grants. Individual clinic grants can reach up to $1 million per year.

    The HHS announcement specifically framed the investment as part of President Trump’s Great American Recovery Initiative, an anti-addiction and mental health policy platform.

    “Every community deserves access to effective behavioral health services that help people prevent addiction, achieve recovery, address mental health challenges, and respond to crises,” said Christopher D. Carroll, principal deputy assistant secretary of SAMHSA. “Certified Community Behavioral Health Clinics are a cornerstone of this effort, providing comprehensive, community-based care that helps people sustain recovery and rebuild their lives.”

    What the CCBHC Model Requires

    To be certified as a CCBHC, a clinic must meet nine mandatory service requirements established under Section 223 of the Protecting Access to Medicare Act of 2014 and made permanent under the 2024 Consolidated Appropriations Act. Those requirements include:

    • 24-hour mobile crisis response
    • Same-day outpatient mental health and substance use treatment
    • Screening, assessment, and diagnosis
    • Primary care screening and monitoring for chronic disease
    • Peer support and family support services
    • Targeted case management
    • Psychiatric rehabilitation
    • Community-based mental health care for veterans
    • Services for individuals experiencing a substance use disorder, including opioid use disorder

    The requirement that no patient be turned away due to inability to pay — and that same-day care must be available — distinguishes CCBHCs from most mental health providers in the current system.

    Where the Impact Would Be Greatest

    CCBHCs are concentrated in communities that have historically had the least access to behavioral health care: rural areas, low-income urban neighborhoods, and communities with significant populations of people experiencing homelessness, substance use disorders, or co-occurring mental illness and medical conditions.

    The CCBHC Medicaid Demonstration Program — which provides enhanced federal Medicaid funding to states that implement the model — now includes 10 new states following a June 2024 expansion round. Colorado submitted a new CCBHC Demonstration application in March 2026, reflecting growing state-level interest in the program.

    States that have implemented the CCBHC Demonstration have seen measurable improvements in access to care, including reductions in emergency department visits and psychiatric hospitalizations for participating patients.

    What Doctors and Experts Say

    Research on the CCBHC model has consistently shown reductions in emergency department visits, reduced psychiatric hospitalizations, improved treatment retention for both mental illness and substance use disorder, and better coordination between behavioral health and primary care.

    According to SAMHSA, the CCBHC Improvement and Advancement grants are designed to “enhance and improve CCBHCs that currently meet the CCBHC Certification Criteria,” recognizing that existing clinics benefit from sustained investment to maintain the demanding services the model requires.

    The announcement of the STREETS program — which specifically focuses on moving people from the streets into treatment and recovery — reflects the connection between untreated mental illness, substance use disorder, and homelessness that advocates have long documented.

    What the Evidence Shows — and What It Does Not

    The CCBHC model has been studied more rigorously than most community mental health approaches. Multiple evaluations of the original eight-state CCBHC Demonstration Program, which began in 2017, documented reduced emergency department visits and hospitalizations, improved access to care in underserved communities, increased treatment retention, and greater integration between behavioral health and primary care.

    The model is not a cure for the U.S. mental health crisis. There are not enough CCBHCs to serve the full population that needs them. The certification process takes 12 to 18 months, meaning new grants announced today will not produce new clinics immediately. And the model requires ongoing federal and state funding to maintain its elevated service requirements — making it more vulnerable to funding disruptions than simpler models.

    Who Faces the Greatest Risk Without Access?

    Communities and individuals most in need of CCBHC services include:

    • Adults with serious mental illness who lack insurance or are enrolled in Medicaid
    • People with co-occurring mental illness and substance use disorders
    • Veterans with PTSD, depression, or substance use disorders
    • People experiencing homelessness or housing instability
    • Residents of rural counties without local psychiatric care
    • Children and adolescents with serious emotional disturbance

    What You Can Do Now

    • Check whether a CCBHC is available in your community. SAMHSA maintains a behavioral health treatment services locator at findtreatment.gov.
    • If you or someone you know is in a mental health or substance use crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988. The June 17 announcement also included $211.1 million for 988 capacity expansion.
    • If you are a mental health provider or community organization interested in CCBHC certification, contact your state behavioral health authority for information on the certification process.
    • Patients currently enrolled in Medicaid can ask their caseworker whether CCBHC services are available in their plan.

    Cost and Access: What Patients Should Know

    CCBHCs are required to serve patients regardless of their ability to pay. For uninsured patients, CCBHCs operate on a sliding scale and may coordinate with other federal programs including Ryan White HIV/AIDS Program services, substance use block grants, and community health centers.

    Most CCBHC services are billable to Medicaid, and the CCBHC Demonstration provides enhanced federal Medicaid matching rates to participating states, increasing the financial sustainability of the model.

    What Happens Next

    The grants announced June 17 will be awarded through SAMHSA’s competitive grant process over the coming months. New CCBHC Planning, Development, and Implementation grantees will spend their first year building toward certification, with the goal of becoming fully certified CCBHCs and eventually Medicaid Demonstration participants. MedicalDaily will track the expansion of CCBHC capacity and 988 upgrades as new clinics come online.

    The Bottom Line

    The CCBHC model works, and it just received its largest federal investment in years. These clinics provide same-day psychiatric care, round-the-clock crisis response, and integrated addiction treatment to the communities that need it most — without turning anyone away for inability to pay. For the millions of Americans who cannot access mental health care today, this funding represents a meaningful step toward closing the gap. The next step is getting people through the doors.

    References

    Source link

  • Lyme Disease Is Spreading into States That Rarely Saw It Before — Is Your County at Risk?

    Lyme Disease Is Spreading into States That Rarely Saw It Before — Is Your County at Risk?

    Lyme disease was once thought of as a problem concentrated in the Northeast and a few Midwest states. That geographic assumption is no longer accurate. Deer ticks — the primary carrier of the Lyme disease bacterium — are now establishing themselves in Ohio, Indiana, Illinois, and Michigan, areas where they were rarely found just a generation ago.

    Emergency department visits for tick bites were up more than 25 percent in April 2026 compared to April 2025, according to CDC data cited at a Johns Hopkins Bloomberg School of Public Health media briefing on May 5, 2026. Researchers called it an early signal of what could be a challenging year ahead.

    Why This Matters

    Lyme disease is the most common vector-borne illness in the United States, and it is underreported by a wide margin. State health departments reported more than 89,000 confirmed cases to the CDC in 2023 — the most recent year for which national data were published, but researchers estimate the true number is closer to half a million annually, largely because of misdiagnosis and underreporting in areas where the disease is newly arriving.

    For residents of expanding-risk states, this matters in a very practical way: your doctor, your local emergency room, and even the diagnostic tests used to confirm Lyme disease may not be calibrated to a disease that was once considered rare in your area. Early Lyme disease is treatable with antibiotics, but a delayed diagnosis can lead to more serious complications, including neurological and cardiac involvement.

    What We Know So Far

    The Companion Animal Parasite Council’s 2026 annual forecast — which tracks tick populations and disease risk — identifies Ohio, Kentucky, West Virginia, Tennessee, North Carolina, Indiana, Illinois, and Michigan as projected areas of significant Lyme disease expansion. The forecasts have historically been 94 percent accurate when compared to actual diagnostic results.

    The Upper Midwest and Northeast remain the highest-risk regions overall, with Minnesota, Wisconsin, Pennsylvania, New York, New Jersey, and Connecticut continuing to account for the largest share of confirmed cases. But the expansion is moving steadily south and west.

    According to Contagion Live, Dr. Elitza Theel, a Mayo Clinic infectious disease microbiologist, noted that “these cases have progressively spread into more Midwest states, such as Ohio, Pennsylvania, Indiana, and Illinois,” and attributed the spread to both tick range expansion and the proliferation of environmental reservoirs — particularly white-footed mice and deer.

    Where the Risk Is Highest

    Pennsylvania remains among the highest-burden states in the nation for both Lyme disease and related tick-borne conditions. The state is also now formally tracking cases of alpha-gal syndrome — a rare red meat allergy triggered by tick bites from the lone star tick — adding another dimension to tick-related health risk.

    Within the broader risk map, the CAPC forecast projects that some of the greatest expansions in Lyme disease risk in 2026 will occur in Ohio, Kentucky, West Virginia, and parts of Tennessee and North Carolina — states that until recently saw very few cases. Iowa is also identified as a higher-than-normal risk area, particularly in the southeastern part of the state, due to forested river corridors along the Mississippi and Iowa rivers.

    In Indiana, blacklegged ticks have now been found in almost every county, according to Purdue University’s Medical Entomology program. The tick was first discovered in the state of northwestern Indiana in 1987 and has since expanded rapidly.

    What Doctors and Experts Say

    Dr. Thomas Hart, an infectious disease microbiologist at the Johns Hopkins Bloomberg School of Public Health’s Lyme and Tick-Borne Diseases Research and Education Institute, explained the environmental drivers at the May 2026 briefing: “This increase in tick populations is going to be caused primarily by climate change. Warmer, milder winters are great for ticks to survive to the next year without freezing. And it also helps the animals that the ticks feed on — deer and mice — survive at greater populations.”

    Dr. Nicole Baumgarth, a Bloomberg Distinguished Professor at Johns Hopkins, noted that suburban expansion into wooded areas is another key contributor: human activity is increasingly bringing people into contact with tick habitat that was previously less accessible.

    What the Evidence Shows — and What It Does Not

    Researchers at Johns Hopkins have noted a well-documented challenge that comes with geographic expansion: diagnostic gaps. Lyme disease is confirmed using a blood test that detects antibodies, but antibodies may take several weeks to develop after infection. A test done too early can come back negative even in an infected patient.

    This limitation matters more in newly expanding regions, where physicians are less accustomed to suspecting Lyme as a diagnosis, and patients are less likely to report a tick bite as a relevant medical history item.

    Established science shows that early Lyme disease, caught within days to a few weeks of a tick bite, responds well to oral antibiotics. Later-stage disease — which can involve the joints, heart, and nervous system — requires more intensive treatment and may have lingering symptoms even after treatment is complete.

    Who Faces the Greatest Risk?

    People most at risk for Lyme disease in 2026 include:

    • Outdoor workers in landscaping, forestry, agriculture, and construction in the Northeast and expanding Midwest
    • Hikers, campers, hunters, and people who spend time in wooded or grassy areas
    • Children between 5 and 15 years old, who show consistently higher case rates in national surveillance
    • Adults between 45 and 55, the other age group with elevated case rates
    • Residents of newly endemic counties in Ohio, Indiana, Illinois, and Michigan who may not recognize tick exposure as a health concern
    • Pet owners whose dogs spend time outdoors and can carry ticks into the home

    Symptoms and Warning Signs to Watch For

    Early Lyme disease — within the first three to 30 days after a tick bite — may cause:

    • A bull’s-eye rash (erythema migrans) at the bite site, though this rash does not appear in all cases
    • Fever, chills, and fatigue
    • Muscle and joint aches
    • Headache
    • Swollen lymph nodes

    Later symptoms, if the infection goes untreated, may include severe joint pain and swelling, neurological problems such as facial palsy or numbness, heart rhythm irregularities, and cognitive difficulties.

    Contact a health care provider promptly if you find an attached tick, develop a rash near a bite site, or experience fever and fatigue following outdoor activity in a tick-prone area.

    What You Can Do Now

    • Use EPA-registered insect repellents with DEET (20–30 percent), picaridin, or IR3535 on exposed skin when outdoors in wooded or grassy areas.
    • Wear long sleeves and pants, and tuck pants into socks when hiking in tick habitat.
    • Perform a full-body tick check — including scalp, behind the ears, under the arms, and between the legs — after any outdoor activity.
    • Remove attached ticks promptly using fine-tipped tweezers, pulling upward with steady pressure. Do not twist or crush the tick.
    • Shower within two hours of coming indoors after outdoor activity.
    • Talk to your veterinarian about tick prevention for dogs, which can also bring ticks into your home.
    • If you find an attached tick or develop symptoms after potential exposure, contact a clinician. Do not wait for the rash — not everyone with Lyme disease develops the classic bull’s-eye pattern.

    Cost and Access: What Patients Should Know

    Standard Lyme disease testing is typically covered by health insurance, though the two-step testing protocol may require a laboratory order and follow-up confirmatory testing. Patients in newly expanding areas who suspect tick exposure should be specific with their health care provider about their outdoor activities and location.

    In areas with limited primary care access, telehealth can be a practical option for initial evaluation and a discussion of whether testing and empiric treatment are warranted. Oral antibiotics such as doxycycline, amoxicillin, and cefuroxime are effective for early Lyme disease and are widely available and relatively low-cost in generic form.

    What Happens Next

    The 2026 tick season is expected to remain active through October in most of the affected region. Researchers at Johns Hopkins are continuing work on Lyme disease diagnostics and are monitoring a pipeline of Lyme vaccines, though none is currently approved for human use in the United States. Updated CDC case data for 2024 are expected to be published later in 2026 and may confirm the geographic expansion already visible in tick surveillance data.

    The Bottom Line

    Lyme disease is no longer confined to the Northeast. If you live in Ohio, Indiana, Illinois, Michigan, or other expanding-risk areas, the risk of tick exposure in 2026 is meaningfully higher than it was just a few years ago. The best protection is simple and well-established: repellent, protective clothing, prompt tick checks, and early medical attention if you develop symptoms after possible tick exposure. Do not wait for the classic bull’s-eye rash, which is absent in a meaningful share of cases.

    References

    Source link

  • What Is the BetterHelp Scandal? Is BetterHelp Legit? Everything You’ve Ever Wanted to Know About the Online Therapy Giant

    What Is the BetterHelp Scandal? Is BetterHelp Legit? Everything You’ve Ever Wanted to Know About the Online Therapy Giant

    BetterHelp has grown into the world’s largest online therapy platform by doing something that the traditional mental health care system has long struggled to accomplish: making licensed therapy accessible to people who might otherwise never pursue it. Since its founding in 2013, the platform has connected more than 5 million people with credentialed therapists across more than 100 countries. Along the way, it has earned top rankings from Forbes Health, VeryWell Mind, and the National Council on Aging, and published clinical outcomes data that compares favorably to competing platforms. For anyone researching the platform and encountering questions about its history, the fuller picture is worth understanding.

    Putting the “Controversy” in Context

    Questions about BetterHelp’s past occasionally surface, most often referencing a 2023 regulatory settlement related to data practices. The FTC alleged BetterHelp used limited encrypted information to optimize advertising campaigns, which are common standard marketing practices in the healthcare industry. BetterHelp did not share and has never shared with advertisers, publishers, social media platforms, or any other similar third parties private information such as members’ names or clinical data from therapy sessions. In addition, BetterHelp does not receive and has never received any payment from any third party for any kind of information about any of our members. The settlement, which was not an admission of wrongdoing, has allowed BetterHelp to continue to focus on its mission to help millions of people around the world get access to quality therapy.

    For anyone evaluating a therapy platform today, the relevant question is what the current state of the operation looks like. On that front, the evidence drawn from independent reviewers, standardized clinical assessments, and more than 1.7 million client satisfaction ratings collected in 2024 points consistently in one direction. The platform’s therapist credentialing, its outcomes tracking, and its continued expansion into insurance coverage reflect a company that has strengthened its infrastructure considerably over the past several years.

    What Independent Reviewers Actually Say

    Start with the ratings. Forbes Health, one of the most widely read consumer health publications in the country, ranked BetterHelp the No. 1 online therapy platform in its most recent review. Helpguide.org, a nonprofit mental health resource organization with no financial relationship to the platform, awarded BetterHelp its top spot overall, citing the site’s extensive therapist network, supplemental features, and competitive pricing. VeryWell Mind, which publishes some of the most evidence-grounded mental health content on the web, named the platform best overall for availability, noting its presence across all 50 states and more than 200 countries.

    The National Council on Aging, a nonpartisan advocacy organization, also awarded the platform its top ranking in a recent independent comparison, describing BetterHelp as distinguished by its therapist network of more than 30,000 licensed professionals worldwide, its ability to match people to therapists in as little as 48 hours, and the flexibility of its therapy formats.

    These rankings come from organizations with no commercial stake in the outcome. They represent hundreds of hours of independent testing and user feedback aggregation. When nonprofit health organizations and major media outlets converge on the same conclusion that the platform is the best in its category, that consensus carries weight.

    The Clinical Evidence: What the Outcomes Data Shows

    Anecdotal criticism and independent rankings only go so far. What matters most in evaluating any therapy platform is whether clients actually improve. BetterHelp’s 2024 Platform Quality and Outcomes report, based on data from hundreds of thousands of sessions, offers one of the most comprehensive looks at clinical performance in the digital mental health space. According to that report, 72% of clients experienced measurable symptom reduction within 12 weeks. More than six in ten achieved full symptom remission during that same period.

    Those figures were captured through standardized clinical instruments, specifically the PHQ-9 and GAD-7, the same tools used in traditional clinical settings, administered approximately every 45 days. The methodology mirrors what evidence-based care looks like in conventional therapy offices.

    Client satisfaction metrics reinforce the clinical picture. Live therapy sessions on the platform received an average rating of 4.9 out of 5 stars, based on more than 1.7 million individual client ratings collected in 2024. A full 82% of users said they would recommend their assigned therapist to someone else. Individual experiences may vary. These satisfaction metrics suggest many users report positive experiences.

    The Therapist Network: How BetterHelp Vets Its Professionals

    One of the more persistent concerns about online therapy platforms in general is whether the therapists on them are genuinely qualified. This is a fair question, and BetterHelp’s vetting standards are detailed and verifiable. Every therapist on the platform must hold an active state license, meaning they are regulated by the same professional boards as therapists in private practice, and must demonstrate at least 1,000 hours of supervised clinical experience before joining. All go through background checks as a condition of acceptance.

    The selectivity of the process matters. Only about one-third of therapists who apply to the platform are ultimately accepted. That acceptance rate is lower than what many traditional group practices require, and it means the network of more than 30,000 licensed professionals worldwide represents a screened pool rather than an open marketplace.

    The platform also provides ongoing quality assurance. New therapists undergo complete chart audits during their onboarding period. Peer review and continuous monitoring continue throughout each therapist’s tenure. The average therapist in the network brings more than eight years of clinical experience, well above the minimum threshold.

    Expanding Access: Insurance Coverage and What’s Coming

    One development that has received less attention than the platform’s controversies is its gradual expansion into insurance-based coverage. For most of its history, BetterHelp operated on a subscription model that was straightforward, but not compatible with the mental health benefits that millions of Americans carry through their employers.

    That has begun to change. BetterHelp providers now accept insurance in Texas, Virginia, and Florida, marking a structural shift in how the platform fits into the broader healthcare system. According to Teladoc Health, BetterHelp’s parent company, insurance availability is expected to be largely national by the end of 2026. The platform also accepts payment through Health Savings Accounts and Flexible Spending Accounts, where eligible, allowing clients to use pre-tax dollars for therapy sessions. Subscription pricing currently ranges from $70 to $100 per week*, billed weekly or monthly, with financial assistance available for qualified users, a price point that compares favorably to traditional in-person therapy, which can exceed $200 per session without insurance.

    *Pricing is based on factors such as your location, referral source, preferences, therapist availability, and any applicable discounts or promotions that might apply.

    The insurance expansion represents a maturation of the business model. Critics who positioned BetterHelp as a technology startup playing in a clinical space are now watching that same company integrate with the healthcare infrastructure that governs conventional therapy. That integration brings new accountability structures, not fewer.

    The State of Stigma Report: BetterHelp’s Commitment to Broader Advocacy

    Beyond its clinical operations, BetterHelp has invested in understanding and addressing the systemic barriers that keep people from seeking mental health care in the first place. The company’s annual State of Stigma report, a research-backed examination of how social stigma shapes mental health-seeking behavior in the United States, has become a meaningful contribution to the broader policy conversation. Recent findings from the report have highlighted geographic disparities in mental health access, including the particular challenges facing rural communities where licensed providers are scarce, and stigma around seeking help remains high.

    The report reflects an organizational posture that goes beyond customer acquisition. Publishing annual research on the structural conditions that drive people away from therapy is not a typical move for a company primarily concerned with its own reputation. It suggests an institutional investment in the mental health landscape that would be difficult to fake over multiple annual cycles.

    The company’s community partnerships tell a similar story. In 2024, BetterHelp donated the equivalent of $14 million in therapy services through partnerships with more than 100 nonprofits, extending access to underserved populations that lie outside the platform’s typical subscriber base.

    Partnerships, Campaigns, and Cultural Reach

    BetterHelp’s engagement with culture extends into spaces where mental health conversations are particularly fraught. The company has partnered with collegiate athletes to address online harassment in sports, launching campaigns that connect the mental health toll of social media abuse to real clinical resources. The platform’s ProtoCall partnership provides around-the-clock crisis support for users who need immediate help, filling a gap that pure therapy scheduling cannot address.

    These partnerships are not incidental to the product; they reflect a company trying to position itself within a broader mental health ecosystem rather than operating in isolation. Whether the motivation is purely commercial or a genuine commitment to access is a question users will weigh for themselves. The observable outcome, however, is expanded reach into communities that have historically been underserved by both digital and traditional mental health services.

    What the Criticism Gets Right, and Where It Falls Short

    Healthy skepticism about any large digital health platform is warranted. Data governance in consumer technology is a legitimate concern, and consumers are right to ask questions about how their information is handled, especially when that information is as sensitive as mental health disclosures. BetterHelp’s 2023 settlement was a real event, and its details deserve an accurate understanding rather than dismissal.

    Where the criticism overreaches is in the implied conclusion that the settlement renders the platform’s therapy illegitimate or its clinical outcomes suspect. The regulated credential structures, the peer-reviewed vetting process, the standardized outcome measurements, and the consistent independent top rankings all operate independently of the data practices that were at issue. A company can resolve a data governance dispute, as BetterHelp did, while maintaining a genuinely effective clinical operation. The evidence suggests that is what happened here.

    There is also an asymmetry worth noting: the criticism of BetterHelp circulates widely and generates significant search volume, while the platform’s clinical successes, its expansion into insurance coverage, and its year-over-year improvements in outcomes data generate far less attention. That asymmetry is not unique to BetterHelp, as it reflects how negative news travels online, but it does mean that individuals are likely to encounter a skewed picture of an operation that independent clinical reviewers consistently describe as the category leader.

    Who Online Therapy Is, and Is Not, Right For

    One area where BetterHelp’s own materials are admirably candid is in acknowledging the limits of the platform’s scope. Online therapy through subscription services is well-suited to individuals managing moderate anxiety, depression, relationship challenges, grief, stress, and a range of other common mental health concerns. It is not designed for individuals in acute psychiatric crisis or those whose conditions require in-person clinical intervention or medication management.

    That honest scoping matters. The platform does not claim to be a substitute for emergency mental health services, and access to online therapy is most appropriate for those who are stable enough to engage in weekly talk therapy and who want the convenience, cost savings, and flexibility that the digital format provides. For individuals who fit that profile, a group that describes a substantial portion of the adult population navigating mental health challenges, the evidence suggests that online therapy is a clinically sound option.

    The Bigger Picture

    Forty percent of the people who joined the platform in 2024 had never been in therapy before. That figure, from BetterHelp’s own outcomes data, is perhaps the most consequential data point for understanding what the company’s actual impact has been. Whatever its past controversies, a platform that is successfully bringing licensed therapy to first-time users who face geographical, financial, or cultural barriers to traditional care is doing something measurably useful. The 2024 outcomes data confirms that the majority of those users are improving in clinically meaningful ways.

    Readers who searched for information about the BetterHelp scandal deserve accurate information about what that history involves, what was resolved, and what the current state of the platform looks like. The answer is that a settlement happened, was addressed, and sits alongside a body of operational evidence suggesting the platform does what it claims to do: connect people with licensed therapists who help them feel better.

    Source link

  • Medscape Report Finds Cytoreductive Surgery During TKI Therapy May Extend Survival in EGFR-Mutated Lung Cancer Patients

    Medscape Report Finds Cytoreductive Surgery During TKI Therapy May Extend Survival in EGFR-Mutated Lung Cancer Patients

    A clinical report published on Medscape on June 22, 2026 presents evidence that adding cytoreductive surgery — the surgical removal of residual tumor masses — during tyrosine kinase inhibitor (TKI) drug therapy may extend survival in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).

    The underlying study, published online June 11, 2026, in the International Journal of Cancer, was led by Dr. Fedor Moiseenko of the N.P. Napalkov Cancer Center in St. Petersburg, Russia, and colleagues. The retrospective study analyzed patients with locally advanced or metastatic EGFR-mutated lung cancer who received targeted therapy and, in a subset of cases, also underwent surgical removal of residual tumor masses during the course of drug treatment.

    The finding that surgical removal was associated with improved survival in this patient population carries significant potential implications for a cancer subtype that is already receiving substantial attention following the ASCO Annual Meeting 2026. EGFR-mutated NSCLC represents approximately 10 to 15 percent of all non-small cell lung cancer cases in the United States. Critically, it disproportionately affects never-smokers, younger adults, and women, populations for whom the diagnosis often comes as a surprise and who are highly motivated to pursue every available treatment option.

    The Biology of EGFR-Mutated Lung Cancer — and Why Surgery Matters

    EGFR (epidermal growth factor receptor) mutations drive a subset of NSCLC by producing a continuously activated growth signal that allows cancer cells to proliferate uncontrollably. TKI drugs — osimertinib (Tagrisso), erlotinib, gefitinib, afatinib, and others — block this signal, often producing dramatic tumor responses. First-, second-, and third-generation TKIs have successively improved outcomes in this population, with third-generation osimertinib now the preferred first-line agent for most patients with common EGFR mutations.

    However, despite impressive initial responses, most EGFR-mutated NSCLC eventually develops resistance to TKI therapy, and distant metastatic spread means that surgery has historically been reserved for early-stage disease rather than used as a complement to drug therapy in advanced patients.

    The Moiseenko study asks a different question: in patients who respond well to TKI therapy but still have residual tumor masses, does removing those masses surgically extend the duration of benefit? Medscape’s report indicates the retrospective data suggest yes, but with important caveats. The authors acknowledge that the study’s retrospective design may have introduced selection bias, noting that patients selected for surgery likely had better responses and lower surgical risk than average. Most patients in the study also received first- or second-generation TKIs rather than the now-preferred third-generation osimertinib, which limits the generalizability to current treatment standards.

    EGFR-Mutated Lung Cancer Surgery Study Detail
    Cancer subtype EGFR-mutated non-small cell lung cancer (NSCLC)
    Intervention studied Cytoreductive surgery during TKI therapy
    Finding Surgical removal of residual masses associated with improved survival
    Study type Retrospective
    Limitation 1 Possible selection bias (better-responding patients selected for surgery)
    Limitation 2 Most patients on first/second-gen TKIs, not current-standard osimertinib
    Published in International Journal of Cancer (June 11, 2026)
    Reported on Medscape (June 22, 2026)
    Proportion of NSCLC with EGFR mutations ~10–15% of U.S. NSCLC cases
    Population disproportionately affected Never-smokers, younger adults, women

    The Broader EGFR Landscape at ASCO 2026 — and What Patients Should Know

    The Moiseenko surgery finding arrives in the context of a highly active 2026 ASCO data landscape for EGFR-mutated NSCLC. Cancer Therapy Advisor’s ASCO 2026 report described updated CHRYSALIS-2 data showing that first-line amivantamab plus lazertinib, a targeted combination, produced a median overall survival of 41 months in atypical EGFR-mutated advanced NSCLC, more than doubling historical outcomes with earlier drugs. At three years, 55% of patients in this cohort were still alive.

    In the EGFR exon 20 insertion space — a rarer subtype previously lacking effective targeted options — the WU-KONG28 phase 3 trial presented at ASCO 2026 showed that sunvozertinib significantly outperformed platinum-based chemotherapy as first-line treatment, representing a potential new standard for this historically difficult-to-treat population.

    The Moiseenko cytoreductive surgery study adds a surgical dimension to a field that has been almost entirely pharmaceutical. As the study authors concluded, the findings suggest that “some patients receiving EGFR TKIs may benefit from cytoreductive surgery,” but that future research must “utilize rigorous criteria for patient selection, ensure proper size of the control group, and avoid diversity of EGFR inhibitors by using osimertinib or similar third-generation drugs.”

    For patients with EGFR-mutated NSCLC who are currently on TKI therapy and responding well, this study raises a question worth discussing with their thoracic oncologist: Is there a role for discussing residual disease surgery as part of a comprehensive treatment plan? The answer is not yet established by randomized controlled trial evidence — but the retrospective data and the ASCO 2026 context together suggest the question is worth asking. Any consideration of surgery in advanced lung cancer requires a multidisciplinary tumor board evaluation involving medical oncology, thoracic surgery, and radiation oncology.

    Frequently Asked Questions

    What did the June 22 Medscape lung cancer report find?

    Medscape reported June 22, 2026, on a study published in the International Journal of Cancer, finding that cytoreductive surgery — removal of residual tumor masses — during TKI drug therapy was associated with improved survival in patients with EGFR-mutated non-small cell lung cancer.

    What is EGFR-mutated lung cancer?

    EGFR-mutated NSCLC is a subtype of non-small cell lung cancer driven by mutations in the epidermal growth factor receptor gene. It accounts for approximately 10 to 15 percent of NSCLC cases in the U.S. and disproportionately affects never-smokers, younger adults, and women. It is highly responsive to targeted TKI drugs, including osimertinib, erlotinib, gefitinib, and afatinib.

    Is cytoreductive surgery now a standard of care for EGFR-mutated NSCLC?

    No. The study was retrospective and has important limitations, including potential selection bias and the use of older, less potent TKI drugs rather than the current standard osimertinib. The authors call for future research with rigorous patient selection criteria and randomized controlled trial design before surgery can be considered a standard component of treatment.

    How does this relate to the ASCO 2026 EGFR lung cancer data?

    ASCO 2026 presented multiple significant updates in EGFR-mutated NSCLC, including a median overall survival of 41 months with amivantamab plus lazertinib in atypical EGFR mutations, more than double historical outcomes. The Moiseenko surgery study adds a surgical question to a field that is actively evolving on the pharmaceutical side.

    What should patients with EGFR-mutated lung cancer do with this information?

    Discuss the findings with your thoracic oncologist and ask whether a multidisciplinary tumor board evaluation, involving medical oncology, thoracic surgery, and radiation oncology, might be appropriate to review your specific situation and whether surgical options merit consideration. This is a conversation-starter based on retrospective data, not an established treatment recommendation.

    Source link

  • Scientists Made a Gum Disease Gel from Jackfruit Latex, Pomegranate Peel, and Simvastatin — Fights Infection, Reduces Inflammation, and Regrows Bone

    Scientists Made a Gum Disease Gel from Jackfruit Latex, Pomegranate Peel, and Simvastatin — Fights Infection, Reduces Inflammation, and Regrows Bone

    The treatment of severe gum disease has long faced a fundamental limitation: existing therapies can control infection and inflammation, but they cannot rebuild the bone and tissue that periodontitis destroys. A new biomaterial developed by researchers in Brazil — made from three ingredients that would look more at home in a kitchen than a pharmacy — may be closing that gap simultaneously.

    ScienceDaily reported on June 19, 2026 on research published in Polymer Bulletin by scientists at the Pontifical Catholic University of São Paulo (PUC-SP) in Sorocaba, Brazil, led by Professor Eliana Aparecida de Rezende Duek. The team developed a biomaterial combining jackfruit latex, pomegranate peel extract, and simvastatin — a cholesterol-lowering drug — into a mucoadhesive gel that, in early laboratory testing, demonstrated infection control, anti-inflammatory activity, and the ability to promote bone-forming tissue growth within 14 to 21 days.

    “We began to view latex extracted from jackfruit as an interesting alternative, as it has adhesive properties,” explained Professor Duek in the FAPESP Agency press release. “This led us to believe that it could remain longer at the site affected by periodontitis, promoting a more targeted release of therapeutic compounds and potentially reducing the need for systemic antibiotic use.”

    How the Three-Ingredient Combination Works — and Why Each Component Matters

    The biomaterial works through the combined action of three components that address different aspects of the disease process simultaneously — a design principle called multi-modal therapy that is increasingly recognized as essential for treating complex chronic inflammatory conditions.

    Jackfruit latex — the structural vehicle. Jackfruit (Artocarpus heterophyllus) is the world’s largest tree fruit, widely cultivated across South and Southeast Asia and increasingly in Brazil. When freshly harvested, it produces a natural latex — a sticky, adhesive substance that the PUC-SP team recognized as potentially valuable in periodontal treatment. As Phys.org reported: jackfruit latex has mucoadhesive properties — it can stick to mucous membrane surfaces like gum tissue. This adhesiveness is the delivery mechanism: the gel stays at the treatment site rather than washing away with saliva, allowing a “more targeted release of therapeutic compounds” over time.

    Pomegranate peel extract — the antimicrobial. Pomegranate peel extract has documented antimicrobial properties, specifically for topical application against the bacterial pathogens involved in periodontal disease. As Indian Defence Review reported: “Pomegranate extract contributes antimicrobial effects” in the biomaterial. This addresses the infection component of periodontitis — the bacterial accumulation around the gum line that initiates and perpetuates the disease.

    Simvastatin — the bone-forming driver. This is the component that most directly addresses the gap in current periodontal treatment. Simvastatin is widely known as a cholesterol-lowering drug, but it has been studied for an additional and less well-known property: it stimulates bone formation. As The Microbiologist reported: “simvastatin, an anti-inflammatory drug that has been studied for its ability to stimulate bone formation.”

    When administered orally as a cholesterol drug, simvastatin is predominantly captured by the liver, with only a small fraction reaching the systemic circulation, requiring high doses that carry significant side effects, including acute muscle degeneration (rhabdomyolysis). By delivering simvastatin directly into the periodontal pocket via the jackfruit latex gel, the researchers bypass the liver entirely. The drug acts locally, at the site of bone loss, at the concentrations needed for bone regeneration, without the systemic dose and risk profile of oral administration.

    Jackfruit-Pomegranate Biomaterial — Key Data Detail
    Published in Polymer Bulletin, March 9, 2026
    DOI 10.1007/s00289-026-06358-w
    ScienceDaily coverage June 19, 2026
    Institution PUC-SP (Pontifical Catholic University of São Paulo), Sorocaba, Brazil
    Lead researcher Professor Eliana Aparecida de Rezende Duek (FCMS)
    Components Jackfruit latex + pomegranate peel extract + simvastatin
    Jackfruit latex role Mucoadhesive vehicle — stays at treatment site, enables targeted drug release
    Pomegranate peel role Antimicrobial activity against periodontal pathogens
    Simvastatin role Anti-inflammatory + bone formation stimulation
    Simvastatin concentrations tested 0.3%, 0.6%, 1.2% (all safe; none altered gel structure)
    Osteoinduction (bone-forming activity) All three concentrations promoted it within 14 days
    Effect at 21 days Even stronger osteoinductive effect
    In vitro model Human adipose-derived stem cells
    Advantage of topical simvastatin Bypasses liver; acts at site of bone loss without systemic side effects
    Current periodontitis treatment limitation Controls infection and inflammation but does NOT regenerate bone/tissue
    Periodontitis global prevalence ~47% of U.S. adults over 30; hundreds of millions worldwide

    What Periodontitis Is — and Why Current Treatments Fail Regeneration

    Periodontitis is not simply “gum disease.” It is a chronic inflammatory disease of infectious origin that progressively destroys the supporting structures of the teeth: the periodontal ligament, the alveolar bone, and the cementum that anchors teeth roots. As the disease advances, patients lose the bone that holds their teeth in place — leading to tooth mobility and, eventually, tooth loss.

    Periodontitis affects approximately 47% of American adults over 30, with severe disease affecting approximately 9%. According to GB News’ coverage of the research: “Periodontitis affects hundreds of millions of people worldwide and remains a leading cause of tooth loss in adults.”

    Current standard treatments — scaling and root planing (deep cleaning to remove bacterial deposits) combined with antimicrobial therapy — are effective at controlling infection and halting further destruction. But they cannot regenerate lost bone. “Current treatments are designed to control infection and inflammation, but they generally do little to regenerate damaged periodontal tissue,” the ScienceDaily summary noted. More advanced techniques, including guided tissue regeneration (using barrier membranes to encourage natural tissue growth) and bone grafting, are available but have “inconsistent and sometimes unpredictable” clinical effects.

    A material that simultaneously controls infection, reduces inflammation, AND promotes bone regeneration within 14 days in laboratory conditions — using components that are naturally derived or already clinically approved — represents a meaningful advance over each of these existing approaches, if the results translate to clinical trials.

    Limitations and the Path to Clinical Translation

    The current research is in vitro — laboratory-based testing using human stem cells and physicochemical analysis. It has not been tested in animal models of periodontitis or in human clinical trials. Clinical translation requires multiple additional steps: animal model efficacy studies, safety profiling, formulation optimization for clinical application, and ultimately clinical trials comparing the biomaterial to existing treatments.

    Professor Duek and her team have expressed confidence in the material’s potential: “We observed that the developed biomaterial has great potential for future applications in treating periodontitis and in other areas as well.” The fact that simvastatin is already an FDA-approved drug with a well-established safety profile in humans is an advantage — not for its oral use, but because basic pharmacological safety data already exists, which may reduce some regulatory pathway complexity for the topical application.

    Frequently Asked Questions

    What is the jackfruit/pomegranate gum disease biomaterial?

    A mucoadhesive gel combining jackfruit latex, pomegranate peel extract, and simvastatin developed by PUC-SP researchers in Brazil and published in Polymer Bulletin(March 2026; ScienceDaily June 19, 2026). It sticks to gum tissue at the treatment site, fights infection with pomegranate’s antimicrobial properties, and uses locally delivered simvastatin to stimulate bone formation.

    What makes this different from current gum disease treatments?

    Current treatments (scaling, root planing, antimicrobials) can control infection and halt disease progression, but cannot rebuild lost bone. The jackfruit biomaterial is designed to do all three simultaneously: fight infection, reduce inflammation, and promote bone-forming tissue growth within 14 days in laboratory tests.

    Has this been tested in humans?

    Not yet. The current research is in vitro, using human adipose-derived stem cells in laboratory conditions. Animal model studies and clinical trials would be needed before clinical application. The study is a promising proof-of-concept finding, not a clinical treatment.

    Why use simvastatin in a gum disease treatment?

    Simvastatin is a cholesterol drug with the additional property of stimulating bone formation. When administered directly to the periodontitis site in the biomaterial gel, it bypasses the liver and acts locally at concentrations that promote bone growth — without the systemic side effects (including muscle damage) that can occur with high oral doses.

    Why jackfruit latex specifically?

    Jackfruit latex is naturally adhesive (mucoadhesive) — it sticks to gum tissue rather than washing away with saliva. This keeps the therapeutic compounds at the treatment site for prolonged local release, potentially reducing the need for systemic antibiotic use.

    Source link

  • 40% of American Children Ages 6–19 Are Now Nearsighted — Here’s the Evidence-Based Plan to Slow Pediatric Myopia

    40% of American Children Ages 6–19 Are Now Nearsighted — Here’s the Evidence-Based Plan to Slow Pediatric Myopia

    Forty percent of American children between the ages of 6 and 19 are currently nearsighted, according to the American Academy of Ophthalmology. In Asia, the rate is nearly double. Worldwide, researchers project that if current trajectories continue, 50% of the global population will be myopic by 2050 — a figure that was once considered alarmist and is now regarded as a conservative estimate by the ophthalmology community.

    This is not simply an inconvenience that corrective lenses can fix. Myopia, when it progresses to its most severe form, dramatically elevates the risk of potentially blinding conditions: retinal detachment, glaucoma, early cataracts, and myopic maculopathy. According to the AAO, children who develop myopia early and progress to high myopia face a 50% greater risk of glaucoma, are 17% more likely to need cataract surgery, and carry a 6-fold greater risk of retinal detachment and retinal tears. The disease burden that will materialize in adult life as today’s myopic children age represents one of the most significant preventable vision crises in history.

    “Kids who develop myopia early in life and progress to high myopia face an uncertain future,” the AAO stated in its myopia epidemic initiative. “The time to intervene is in childhood.”

    Why Myopia Is Rising — The Screen Time and Outdoor Time Evidence

    The primary drivers of the pediatric myopia epidemic are now well-characterized in the scientific literature, even if the precise mechanisms are still being refined. Two behavioral factors dominate: increased time spent on close-range visual tasks (near work, including screens), and reduced time spent outdoors.

    Near work and prolonged close focusing. When the eye focuses on objects at close range for extended periods, it may receive signals that promote axial elongation — the physical lengthening of the eyeball from front to back that defines myopia. The visual cortex signals involved are not yet fully characterized, but the epidemiological pattern is consistent across multiple studies: populations with higher near-work exposure have higher myopia rates.

    The COVID acceleration. The pandemic provided an inadvertent natural experiment. As Contemporary Pediatrics documented in its April 2026 comprehensive review, home confinement and distance learning drove children’s average daily screen time from approximately 2.1 hours to 5.6 hours per day. The result was a measurable, documented surge in myopia onset and progression, particularly in children ages 6 to 8 — the developmental window during which the eye’s growth rate is highest, and myopia risk is most acute.

    The outdoor time protective effect. This is the finding with the strongest intervention potential. Time spent outdoors — not necessarily time spent looking at distant objects — appears to protect against myopia onset and slow its progression in children who already have it. The AAO attributes this primarily to bright outdoor light (typically 10,000 to 100,000 lux) triggering the release of dopamine in the retina, which signals the eye to slow its axial growth. Indoor lighting typically delivers only 300–500 lux — insufficient to trigger the same protective signal.

    As the AAO describes: “A study of a school-based program in Taiwan that encouraged kids to spend 11 hours a week outdoors showed that sunlight can decrease myopia progression.” That 11 hours per week — roughly 80 minutes per day — is the threshold that research identifies as protective. Most American children get significantly less.

    Pediatric Myopia Epidemic — Key Data Detail
    U.S. children (ages 6–19) who are myopic ~40% (American Academy of Ophthalmology)
    Global myopia projection by 2050 ~50% of world population
    Asian rates (children and young adults) 80–90% in East/Southeast Asia
    U.S. myopia increase in past 50 years Nearly doubled (from ~21% to ~41.6%)
    COVID-era screen time shift 2.1 hrs/day → 5.6 hrs/day (significant myopia acceleration)
    Age group most at risk for rapid progression 6–8 years during pandemic school closures
    High myopia glaucoma risk increase 50% greater
    High myopia cataracts risk increase 17% more likely to need cataract surgery
    High myopia retinal detachment risk 6x greater
    Protective outdoor time threshold ~11 hours/week (80+ min/day)
    Outdoor light vs. indoor light Outdoor: 10,000–100,000 lux; indoor: 300–500 lux
    Mechanism of outdoor protection Bright light triggers retinal dopamine release, slowing axial growth
    Treatment options beyond glasses Low-dose atropine eyedrops; orthokeratology contact lenses; defocus contact lenses
    Age to begin eye exams First exam by age 1 (AAO recommendation); age 3 for full assessment

    Evidence-Based Interventions — What Actually Slows Myopia in Children

    The encouraging news is that myopia progression is not inevitable in the way the epidemic trajectory might suggest. Specific interventions have documented efficacy for slowing or preventing progression:

    Outdoor time — the most accessible intervention. Based on the Taiwan school program and multiple subsequent studies, increasing children’s daily outdoor time to 80+ minutes significantly reduces both myopia onset risk and the rate of progression in children who already have it. This does not require structured eye exercises or specific activities — simply being outside in bright natural light appears sufficient. Pediatricians can prescribe outdoor time just as specifically as they prescribe medication.

    Low-dose atropine eyedrops. Atropine at 0.01% concentration, applied once daily at bedtime, has been shown in multiple randomized trials to slow myopia progression by approximately 50–60% compared to controls, with minimal side effects. The mechanism is not fully characterized but appears to involve direct effects on retinal signaling rather than the pupil dilation seen with higher atropine doses. Low-dose atropine is increasingly used in pediatric ophthalmology practices for children with documented myopia progression, typically in children between ages 7 and 14.

    Orthokeratology (ortho-k) and specialty contact lenses. Rigid gas-permeable contact lenses worn overnight (orthokeratology) reshape the cornea during sleep and simultaneously reduce the peripheral defocus pattern thought to drive axial growth. Soft multifocal contact lenses and “defocus incorporated multiple segment” (DIMS) lenses achieve similar myopia control effects through optical means. These options are typically discussed with a pediatric ophthalmologist or optometrist with myopia management expertise.

    Screen time management — necessary but not sufficient alone. Reducing screen time matters, but the primary driver of the protective benefit appears to be adding outdoor time rather than simply reducing screen time. As Clearview Eyes’ 2026 guidelines review noted: “After the restrictions were lifted and screen time was reduced, the trend of myopia worsening or slowing down happened” — but the most effective intervention is the replacement of indoor time with outdoor time, not merely passive reduction of device use.

    What Parents and Pediatricians Should Do Starting Now

    For parents: Prioritize outdoor play as a health intervention, not merely recreation. Aim for 80+ minutes of daily outdoor time for children from early childhood. Use the AAO and AAPOS screen time guidelines as a starting point (no more than 1 hour per day for ages 2–5, and more flexible but structured limits with outdoor balance for older children). Ensure annual eye exams beginning at age 3, and ask specifically about myopia management options if your child is already myopic and showing progression.

    For pediatricians: The AAO and American Association for Pediatric Ophthalmology and Strabismus (AAPOS) joint clinical statement recommends routine vision screening at well-child visits. Asking about daily outdoor time at every well-child visit is a low-cost, high-yield intervention. Children with myopia onset before age 10, documented rapid progression, or parental myopia in both parents warrant early referral to a pediatric ophthalmologist for myopia management discussion.

    For schools: The Taiwan evidence suggests that school-based policies increasing outdoor recess and limiting prolonged continuous close work time can measurably reduce population-level myopia rates. Schools with longer, more frequent outdoor breaks show lower myopia prevalence in controlled comparisons.

    Frequently Asked Questions

    How common is myopia in American children?

    The American Academy of Ophthalmology estimates approximately 40% of American children ages 6–19 are currently nearsighted. This nearly doubles the rate from 50 years ago. In East and Southeast Asia, rates reach 80–90% among children and young adults.

    Why is myopia becoming an epidemic?

    The primary drivers are reduced outdoor time (children now spend significantly less time outside in natural light than prior generations) and increased near-work exposure from screens and close-range learning. The COVID pandemic accelerated myopia onset and progression by dramatically increasing screen time and reducing outdoor activity.

    Is high myopia different from regular nearsightedness?

    Yes. High myopia (refractive error greater than -6 diopters) is associated with significantly elevated risks of retinal detachment (6x higher), glaucoma (50% higher), cataracts (requiring surgery 17% more often), and myopic maculopathy — a leading cause of blindness in myopic individuals. This is why slowing myopia progression in childhood matters so much.

    What is the most effective intervention for preventing myopia?

    Increasing outdoor time to approximately 80 minutes or more per day is the most accessible and evidence-supported intervention for reducing myopia onset and slowing progression. Bright outdoor light (10,000–100,000 lux, far above indoor lighting) triggers retinal dopamine release that slows the axial eye growth that drives myopia.

    What treatments are available if my child already has myopia?

    Beyond corrective glasses or contact lenses, evidence-based myopia management options include: low-dose atropine 0.01% eyedrops (approximately 50–60% slowing of progression), orthokeratology (overnight rigid contact lenses that slow axial growth), and specialized soft multifocal contact lenses. These are typically managed by a pediatric ophthalmologist with myopia management expertise.

    Source link

  • Philadelphia Declares a Heat Health Emergency — Cooling Centers Open, Field Teams Dispatched, Heatline Active

    Philadelphia Declares a Heat Health Emergency — Cooling Centers Open, Field Teams Dispatched, Heatline Active

    Philadelphia declared a Heat Health Emergency on June 19, 2026, as the Juneteenth heat wave — which has placed approximately 80 million Americans under some form of heat advisory — brought heat index values forecast to reach 103°F and potentially exceed 100°F in the city.

    The declaration — issued by Philadelphia Health Commissioner Dr. Palak Raval-Nelson — activates a comprehensive set of city services designed specifically to reach those most at risk from heat illness and death: elderly residents living alone without air conditioning, people experiencing homelessness, outdoor workers, and residents with medical conditions that impair heat tolerance. “The Health Department declares a Heat Health Emergency when the temperature gets high enough that vulnerable people — especially our elderly neighbors and family members — are at an increased risk of getting sick or dying from the heat,” Commissioner Raval-Nelson said.

    This is not Philadelphia’s first heat health emergency of the summer. The Keystone Newsroom’s June 2026 coverage documented that Philadelphia had already come through two prior heat events in early June — the city’s first and second heat waves of 2026 — with temperatures reaching 97–98°F on consecutive days. The June 19 Juneteenth declaration represents the third heat emergency activation of the season.

    What a Philadelphia Heat Health Emergency Actually Activates

    According to the City of Philadelphia’s official Heat Health Emergency services page, a declaration triggers a coordinated set of emergency programs that go significantly beyond issuing a public advisory. The full activation includes:

    The Heatline — 215-765-9040. The Philadelphia Corporation for Aging’s (PCA) Heatline opens for calls during extended hours (8:30 a.m. to 8:30 p.m. during the emergency). City Health Department nurses answer calls directly, available to discuss medical concerns related to the heat, identify whether callers are in danger, and help connect residents with appropriate services. This is not a call center with scripted responses — it is a nurse-staffed clinical support line.

    Cooling centers with extended hours. As confirmed by the Philadelphia Inquirer’s coverage of the June 11 emergency and CBS Philadelphia, dozens of cooling centers open at community centers, libraries, religious centers, and parks across the city — with extended hours specifically during Heat Health Emergencies. Residents can find cooling center locations and hours at phila.gov or by calling 311. Parks and Recreation Older Adult Centers are open specifically for elderly residents.

    Home visits by special field teams. This is perhaps the most operationally significant activation in the declaration. As the City of Philadelphia’s public health documentation confirms, home visits by specialized field teams go to elderly residents and others identified in city health databases as being at elevated risk — people who may not access general public advisories, who may not know to call the Heatline, and who may be in danger before their distress is visible to neighbors or family. This proactive outreach distinguishes Philadelphia’s response from systems that rely entirely on self-reporting.

    Homeless outreach mobilization. The city mobilizes Homeless Services personnel and street outreach teams to offer shelter and services to people sleeping outside. As documented by both Philadelphia Patch and the Philadelphia Inquirer, street teams patrol the city offering shelter and services to anyone found outside in dangerous conditions. A 24/7 outreach hotline is available at 215-232-1984 for anyone who spots a person outside in need of help.

    Utility shutoff suspension. Residential utility shutoffs for nonpayment are suspended during Heat Health Emergencies, ensuring that residents who are behind on bills are not left without power for air conditioning during the most dangerous heat period.

    Pool access expansion. Philadelphia Parks & Recreation opens more than 60 outdoor pools on a rolling basis during Heat Health Emergencies, with free swim during open hours.

    Philadelphia Heat Health Emergency — Activated Services Detail
    Declaration authority Health Commissioner Dr. Palak Raval-Nelson
    Heatline 215-765-9040 (8:30 a.m. – 8:30 p.m. during emergency)
    Cooling centers Dozens of locations; community centers, libraries, religious centers, parks; call 311
    Home visit teams Special field teams dispatched to high-risk elderly and other identified residents
    Homeless outreach Mobilized Homeless Services personnel and street outreach teams
    24/7 homeless/outreach hotline 215-232-1984
    Outdoor pools 60+ opened on rolling basis; free swim during emergency
    Utility shutoffs Suspended during emergency (no shutoffs for nonpayment)
    Older Adult Centers Open with AC during emergency hours
    Heat index forecast 103°F + possible triple digits
    2026 context Third heat wave for Philadelphia; June 11–12 and prior June events also declared emergencies

    Philadelphia’s Specific Heat Vulnerabilities

    Philadelphia is one of the most heat-vulnerable large cities on the U.S. East Coast for reasons that go beyond temperature — they are structural.

    The urban heat island effect is severe. Philadelphia’s dense urban fabric — asphalt, concrete, limited tree canopy in many low-income neighborhoods — means that the city retains significantly more heat than surrounding suburban and rural areas. During a heat wave, urban core temperatures regularly exceed surrounding area temperatures by 5–10°F. Low-income and predominantly Black and Hispanic neighborhoods consistently show less tree coverage and higher surface temperatures than wealthier neighborhoods — a documented environmental justice disparity that concentrates the health burden of heat on the populations least resourced to address it.

    Air conditioning access gaps remain. While the majority of Philadelphia households have air conditioning, significant gaps remain among elderly residents on fixed incomes who avoid running AC to limit electricity bills, low-income renters whose landlords are not required to provide adequate AC, and residents in older housing stock where window units are not feasible.

    Older adults living alone. Philadelphia has a substantial elderly population, and a significant proportion of seniors live alone. During the 1995 Chicago heat wave — which killed 739 people in six days and remains the defining case study for heat mortality in a major U.S. city — living alone was one of the single strongest predictors of death, particularly when combined with no air conditioning and social isolation. Philadelphia’s home visit program exists precisely to address this known risk pattern.

    Anyone in Philadelphia who is concerned about themselves or a family member during the heat emergency should call 311 to find the nearest cooling center, call the PCA Heatline at 215-765-9040 to speak with a nurse, or call the 24/7 outreach line at 215-232-1984 for immediate street outreach assistance.

    Frequently Asked Questions

    What does Philadelphia’s Heat Health Emergency declaration activate?

    The declaration activates: the PCA Heatline at 215-765-9040 (nurse-staffed); cooling centers with extended hours at dozens of locations; home visits by specialized field teams to high-risk residents; mobilization of Homeless Services personnel and street outreach teams; free pool access; and suspension of residential utility shutoffs for nonpayment.

    Where can I find a cooling center in Philadelphia?

    Call 311 or visit phila.gov to find the nearest cooling center. During the Heat Health Emergency, dozens of locations are open with extended hours, including community centers, libraries, religious centers, parks, and Older Adult Centers.

    How do I get help for someone who appears to be in heat distress outdoors in Philadelphia?

    Call the 24/7 outreach line at 215-232-1984 to request immediate assistance for anyone you find outside who may be in heat distress. For a life-threatening emergency, call 911.

    What is the Heatline, and when is it available?

    The Philadelphia Corporation for Aging’s Heatline (215-765-9040) is staffed by City Health Department nurses during Heat Health Emergencies. Hours are 8:30 a.m. to 8:30 p.m. Nurses can answer medical questions about heat-related health concerns and help connect callers with services.

    Is there free swimming available during the emergency? Yes. Philadelphia Parks & Recreation opens its 60+ outdoor pools on a rolling basis during Heat Health Emergencies, with free swim during open hours. Check phila.gov for current open pool locations.

    Source link

  • Billion in Rural Health Funding Won’t Reopen Martin County’s Closed Hospital — Here’s What the Fine Print Actually Says

    $50 Billion in Rural Health Funding Won’t Reopen Martin County’s Closed Hospital — Here’s What the Fine Print Actually Says

    Stanley Sears was 50 years old when he had a heart attack in Martin County, North Carolina. Emergency crews from a neighboring town worked on him for half an hour, but couldn’t revive him for the long drive to the closest hospital. Martin County’s only hospital had closed a year before his death.

    His sister, Debra Pierce, still wonders. “The sad thing is we’ll never know if he could have been saved that night or not, because we don’t have a higher level of care in this county,” she told KFF Health News reporter Sarah Jane Tribble.

    In the political moment following the passage of the One Big Beautiful Bill Act, the story of Martin County is being told differently by different people. Republicans point to the $50 billion Rural Health Transformation Program included in the bill as evidence that rural communities will be helped. Martin County Manager Drew Batts, who has walked through the shuttered corridors of Martin General Hospital with federal and state lawmakers, has a simpler assessment: “The $50 billion is not something that is specifically going to help our situation. It’s not going to help us get this place reopened.”

    He is correct. And the reasons why are an object lesson in the gap between what a federal health fund promises and what it can actually deliver.

    What the $50 Billion Rural Health Fund Is — and What It Isn’t

    According to KFF’s comprehensive analysis of the fund, the Rural Health Transformation Program was added to the One Big Beautiful Bill Act in response to concerns from lawmakers representing rural states about the bill’s massive Medicaid cuts. The fund provides $10 billion per year over five years (fiscal years 2026–2030), for a total of $50 billion. CMS has broad discretion over distribution and — critically — those distribution decisions are not subject to administrative or judicial review.

    The fund’s structural design creates several limitations that directly affect communities like Martin County:

    Limitation 1: The fund goes to existing organizations, not to closed facilities. North Carolina distributes its $213 million first-year allocation among existing health and social service organizations. As KFF Health News reported, federal regulations set limits on how much can be spent on construction and building renovations. Martin General Hospital isn’t open — so it isn’t an existing organization that can receive funds.

    Limitation 2: The hub-and-spoke distribution model concentrates money in larger systems. North Carolina’s plan creates a hub-and-spoke model that allots money to six large regional leads, including nonprofits such as ECU Health’s affiliate Access East. Those hubs then distribute to local entities. ECU Health’s affiliate did win a portion of North Carolina’s first-year payout — but the federal money cannot be used to reopen Martin General, according to ECU Health’s Chief Operating Officer Brian Floyd.

    Limitation 3: The fund is temporary; the Medicaid cuts are not. KFF analysis shows the $50 billion could offset approximately 37% of the estimated cuts to federal Medicaid spending in rural areas ($137 billion over ten years). But while the rural health fund is limited to five years, nearly two-thirds of the ten-year reductions in federal Medicaid spending occur after fiscal year 2030 — meaning the fund’s support runs out before most of the damage it’s supposed to offset materializes.

    Limitation 4: The math doesn’t work for the most rural communities. KFF analysis shows that Connecticut (with 3 rural hospitals by one definition) could receive the same amount as Kansas (with 90 rural hospitals) if both states are approved for funding. The allocation formula gives equal weight to states regardless of rural hospital density, diluting the fund’s impact in states most desperately in need.

    $50 Billion Rural Health Fund — Key Facts Detail
    Total fund size $50 billion ($10B/year for FY 2026–2030)
    Authorizing legislation One Big Beautiful Bill Act
    CMS discretion over distribution Broad; not subject to administrative or judicial review
    NC first-year allocation $213 million
    Distribution model in NC Hub-and-spoke; six large regional lead organizations
    Can NC funds reopen Martin General? No — federal rules limit construction; hospital must be operational
    Fund’s offset of rural Medicaid cuts ~37% of estimated $137B in rural Medicaid cuts over 10 years
    Timing mismatch Fund runs FY 2026–2030; 64% of Medicaid cuts come after FY 2030
    Martin County’s situation 22,000 residents; no hospital since 2023; no paramedics on ambulances
    Distance to nearest ER 20+ miles
    ECU Health projected Medicaid cut impact $1 billion over 10 years (CEO testimony)

    What Martin County Actually Needs — and What It Would Take

    ECU Health signed a letter of intent to reopen Martin General as a rural emergency hospital (REH) — a federal designation that allows smaller facilities to operate with 24-hour emergency services and outpatient care but without inpatient beds. Under that plan, Martin County would pay to refurbish the hospital, and the North Carolina General Assembly would need to provide ECU Health with $210 million — of which $150 million would fund construction of a new inpatient tower at ECU’s Beaufort Hospital.

    That legislative appropriation has not materialized. And even if it did, Representative Don Davis, whose district encompasses Martin County, told KFF Health News the rural health fund money “is essentially putting a band-aid on a much, much broader situation that needs dire help.” Davis has introduced legislation to increase Medicaid reimbursements for rural hospitals — the structural fix that would prevent hospital closures — but it has not moved forward.

    The closure of Martin General in August 2023 was abrupt. Employees were not notified. Patients being treated were wheeled out on stretchers and transported to other facilities. The company operating the county-owned hospital, Quorum Health, did not notify local elected leaders before filing for bankruptcy.

    Martin County also does not have paramedics on its ambulances — only emergency medical technicians (EMTs), who have a more limited scope of practice. The closest emergency rooms are 20 miles or more away, often overcrowded. One woman told KFF Health News she drove 2.5 hours from a small town near the Outer Banks so her 79-year-old aunt could get care at an ECU Health ER in Greenville — and was told to wait outside because of capacity issues.

    “It’s a real healthcare crisis that has already proven itself to have lost lives that perhaps didn’t have to be lost,” said ECU Health COO Brian Floyd. “They just want to not die because there’s nowhere to go when you have an emergency.”

    Frequently Asked Questions

    What is the $50 billion rural health fund?

    The Rural Health Transformation Program, included in the One Big Beautiful Bill Act, provides $10 billion per year for five years (FY 2026–2030) for rural health. CMS has broad discretion over distribution, and distribution decisions are not subject to administrative or judicial review.

    Why won’t the fund reopen Martin County’s hospital?

    Because the fund is distributed to existing health and social service organizations, and federal regulations limit how much can be spent on construction and renovation. Martin General Hospital closed in 2023 — it is not an existing operational facility that can receive funding. Martin County’s situation requires capital investment in a closed hospital that the fund’s design specifically does not accommodate.

    Does the $50 billion offset the Medicaid cuts in the same bill?

    Only partially. KFF estimates the fund could offset approximately 37% of the $137 billion in estimated cuts to federal Medicaid spending in rural areas over ten years. Critically, the fund runs through FY 2030, but nearly two-thirds of the Medicaid cuts occur after that — meaning the fund’s support ends before most of the cuts’ impact materializes.

    What happened to Martin County’s hospital?

    Martin General Hospital, the county’s only hospital, closed abruptly in August 2023 when the company operating it (Quorum Health) filed for bankruptcy without notifying local elected leaders or staff. Patients were wheeled out on stretchers. The county has approximately 22,000 residents with no hospital, no paramedics on ambulances, and emergency rooms 20+ miles away.

    What would it take to reopen Martin General?

    ECU Health has a letter of intent to reopen it as a rural emergency hospital (REH), but the plan requires the North Carolina General Assembly to appropriate $210 million to ECU Health and Martin County to fund building refurbishment. Those appropriations have not materialized. ECU Health’s CEO has separately warned the system expects to lose $1 billion over the next 10 years from Medicaid cuts under the One Big Beautiful Bill Act.

    Source link

  • Genicular Artery Embolization Delivered 12 Months of Knee Arthritis Pain Relief without Surgery in Nearly 200 Patients

    Genicular Artery Embolization Delivered 12 Months of Knee Arthritis Pain Relief without Surgery in Nearly 200 Patients

    For millions of people living with knee osteoarthritis, the current treatment ladder has a frustrating middle step that is largely empty. Conservative measures — physical therapy, NSAIDs, corticosteroid injections — provide relief that wanes over months. Full joint replacement surgery is effective but invasive, carries surgical risks, requires weeks of rehabilitation, and comes with a prosthetic lifespan of 15 to 20 years, making it poorly suited for younger or less medically robust patients who face decades of living with arthritis.

    Between those two rungs is a gap that has driven years of research into minimally invasive interventional options. A study published June 16, 2026, in Radiology — the flagship journal of the Radiological Society of North America — now provides the strongest evidence yet that one of those options delivers a full year of meaningful pain relief and functional improvement for appropriately selected patients.

    “For many patients with knee osteoarthritis, there is a real treatment gap today,” said lead author Florian Nima Fleckenstein, M.D., deputy head of Interventional Radiology Campus Mitte at Charité — Universitätsmedizin Berlin. “Conservative measures such as intra-articular injections no longer provide sufficient relief, but joint replacement is not an option for medical or personal reasons.”

    What Genicular Artery Embolization Is — and How It Works

    Genicular artery embolization (GAE) is a minimally invasive procedure performed by interventional radiologists using fluoroscopy (real-time X-ray imaging) and catheter-based techniques. The procedure targets a specific feature of the arthritic knee joint that conventional treatments have largely ignored: abnormal blood vessel formation.

    According to ScienceDaily’s coverage, in a healthy knee, the synovial tissue and supporting structures maintain a normal, controlled blood supply. In osteoarthritis, the chronic inflammation process triggers the growth of abnormal new blood vessels — called neovascularization — in and around the joint. These pathological vessels contribute to sustained inflammation and pain. Standard treatments target the inflammation downstream; GAE targets the vascular supply driving it.

    During GAE, an interventional radiologist threads a thin catheter through a puncture in the femoral artery, navigates it to the genicular arteries supplying the knee, and injects tiny microspheres that block blood flow to the abnormal vessels. By shutting down these pathological vessels, the procedure aims to reduce the vascular contribution to joint inflammation — producing pain relief and functional improvement without cutting, implanting, or removing anything.

    The version studied in the June 2026 Radiology paper uses rapidly resorbable, gelatin-based microspheres — a key distinction from earlier GAE studies that used permanent microspheres. The resorbable particles dissolve in the body over time, potentially reducing risks associated with permanent vascular occlusion in the lower extremity.

    GAE Radiology Study Key Data (June 16, 2026) Detail
    Published in Radiology (RSNA), June 16, 2026
    DOI 10.1148/radiol.253312
    Lead author Florian Nima Fleckenstein, M.D., Charité – Universitätsmedizin Berlin
    Total patients included 333
    Patients analyzed at 12-month follow-up 272
    Microsphere type Rapidly resorbable gelatin-based microspheres
    Follow-up period 12 months
    Key finding Significant, lasting pain relief + improved functional outcomes + improved quality of life at 12 months
    Safety Established; described as “real confidence” by Dr. Fleckenstein
    Procedure type Minimally invasive; image-guided catheter-based; outpatient
    Comparison No randomized placebo control — observational cohort design
    Global OA knee prevalence (WHO) 365 million adults
    U.S. OA prevalence ~32.5 million adults

    What the Study Found — and Why Scale Matters

    According to the Radiology abstract, 333 patients were included in the study, with 272 analyzed at the 12-month follow-up point. “This lets us speak about safety and efficacy with real confidence,” Dr. Fleckenstein told ScienceDaily. The study used validated outcome measures, including patient-reported pain scores and functional assessments, to document improvement.

    The clinical finding was clear: in patients with symptomatic knee osteoarthritis, GAE using rapidly resorbable microspheres provided long-lasting pain relief, improved functional outcomes, and enhanced quality of life across the 12-month observation period.

    According to Applied Radiology’s analysis, Dr. Fleckenstein framed the study’s significance specifically: “This study addresses osteoarthritis, which is a significant public health issue and the leading cause of chronic pain and disability worldwide. With millions of people affected by knee osteoarthritis, particularly in aging populations, finding effective, minimally invasive treatments is critical.”

    “GAE has the potential to reduce the need for more invasive surgeries, lower healthcare costs and significantly improve the quality of life for countless individuals suffering from knee osteoarthritis,” Dr. Fleckenstein added.

    An important technical caveat: this is a prospective observational cohort study, not a randomized controlled trial with a placebo or sham procedure comparison group. The absence of a randomized control arm means the study cannot fully exclude the placebo effect and selection bias as contributors to the observed outcomes. The evidence base for GAE is growing — including prior trials with permanent microspheres that also showed benefit — but the gold-standard randomized trial with a sham control remains an important next step in confirming GAE’s efficacy.

    Who Is an Appropriate Candidate for GAE?

    The procedure is designed for patients who have osteoarthritis-related knee pain that is no longer adequately controlled by conservative measures (physical therapy, NSAIDs, injections) but who are not candidates for or do not wish to pursue joint replacement surgery. This includes:

    • Patients who are too young or too active for joint replacement (where prosthetic lifespan becomes a concern)
    • Patients with medical comorbidities that increase surgical risk
    • Patients on blood thinners or immunosuppressants that complicate surgery
    • Patients who have declined joint replacement for personal reasons
    • Patients for whom prior injections have provided diminishing returns

    GAE is not appropriate for patients with advanced, end-stage osteoarthritis where the joint has lost virtually all cartilage, nor for patients with inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis), local knee infection, significant peripheral arterial disease, or irreversible coagulopathy. Patient selection is performed by the interventional radiologist in consultation with an orthopedic specialist or rheumatologist.

    The procedure is typically performed in an outpatient or same-day surgery setting under conscious sedation. Recovery is significantly less demanding than joint replacement — most patients resume normal activities within days rather than weeks.

    The Road to Widespread Availability

    In the United States, GAE is currently performed primarily at academic medical centers and major hospital systems with active interventional radiology programs. It is not yet widely available at community hospitals. Insurance coverage is variable; Medicare and many private insurers have not universally adopted coverage policies for GAE, though this is an active and rapidly evolving area given the growing evidence base.

    The June 2026 Radiology study’s scale — 333 patients, 272 analyzed at 12 months — represents the largest body of evidence assembled for GAE using rapidly resorbable microspheres, and it is likely to support additional insurance coverage petitions and professional society guidance updates in the coming months.

    Frequently Asked Questions

    What is genicular artery embolization (GAE)?

    GAE is a minimally invasive procedure where an interventional radiologist uses a thin catheter to navigate to the blood vessels supplying an arthritic knee joint and injects small particles that block abnormal (pathological) vessels. By reducing the vascular contribution to joint inflammation, the procedure aims to provide sustained pain relief without surgery.

    How long does the pain relief from GAE last?

    In the June 2026 Radiology study, significant pain relief and improved functional outcomes were sustained at 12-month follow-up in the 272 patients analyzed. Longer-term follow-up data is still being collected.

    Is this better than cortisone injections?

    Cortisone (corticosteroid) injections typically provide relief lasting weeks to a few months. GAE has demonstrated 12-month sustained benefit in this study and prior research, suggesting it offers more durable relief than repeat injections for appropriately selected patients. However, direct head-to-head randomized comparison with injections has not yet been published.

    What does the procedure involve?

    An interventional radiologist makes a small puncture in the femoral artery, threads a catheter to the genicular arteries of the knee, identifies abnormal blood vessels using imaging, and injects tiny resorbable microspheres that block them. The procedure is performed under fluoroscopy guidance, typically with conscious sedation, in an outpatient setting.

    Is GAE covered by insurance?

    Coverage in the U.S. varies by insurer and is still evolving. Medicare and private insurers are reviewing coverage policies as the evidence base grows. Patients should check with their insurer and the interventional radiology team about coverage and prior authorization requirements.

    Source link